Details:
As a result of agreement, patients in Germany are now able to access GMP-certified quality medical cannabis from STADA through local pharmacies under the brand – CannabiSTADA (cannabidiol), distributed through STADAPHARM, a direct subsidiary of STADA.
Lead Product(s): Cannabidiol,Tetrahydrocannabinol
Therapeutic Area: Gastroenterology Product Name: CannabiStada
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 01, 2021
Details:
Dexilant-Generic (dexlansoprazole) is a proton pump inhibitor (PPI) indicated for healing of all grades of erosive esophagitis (EE), maintaining healing of EE and relief of heartburn & treating heartburn associated with symptomatic non-erosive GERD.
Lead Product(s): Dexlansoprazole
Therapeutic Area: Gastroenterology Product Name: Dexilant-Generic
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
REDUVO™ is a soft gel capsule used to treat chemotherapy-induced nausea and vomiting (CINV). It is also used to treat weight loss and severe nausea in people living with HIV infection.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Gastroenterology Product Name: Reduvo
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
RELISTOR subcutaneous injection (methylnaltrexone bromide), an opioid antagonist indicated for treatment of opioid-induced constipation, The subgroup of patients in OIC-Rx cohort received RELISTOR had 0.7 fewer inpatient days per OIC ED encounter versus No-OIC-Rx cohort.
Lead Product(s): Methylnaltrexone Bromide
Therapeutic Area: Gastroenterology Product Name: Relistor
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
DanCann Pharma will exclusively distribute Tetra Bio's Reduvo™ Adversa®, QIXLEEF™ and ENJOUCA™ in Denmark, Norway, Sweden, Finland, and Germany.
Lead Product(s): Tetrahydrocannabinol
Therapeutic Area: Gastroenterology Product Name: Reduvo Adversa
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: DanCann Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 05, 2021